BiologicalDrug
Lisocabtagene maraleucel clinical trials
Also written JCAR017 and Breyanzi.
Keep track of what changes. Save the lisocabtagene maraleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Breyanzi
- 10
Studies by the year they started
20 studies that test it; most in 2018 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 9
Juno Therapeutics, a Subsidiary of Celgene (4) · Celgene (3) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (3) · Fred Hutchinson Cancer Center (2) · University of Nebraska (1) · City of Hope Medical Center (1) · Patrick C. Johnson, MD (1) · Masonic Cancer Center, University of Minnesota (1)
Often tested with
Tested in the same studies.
Tisagenlecleucel (3) · Axicabtagene ciloleucel (3) · Fludarabine (2) · Cyclophosphamide (2) · Ibrutinib (1) · Nivolumab (1) · Acalabrutinib (1) · Brexucabtagene autoleucel (1)
Studies
Open first, then newest update. How each study uses lisocabtagene maraleucel is read from its arms, and is right about nine times in ten.
Testing it · 20
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingPhase 2Massachusetts General HospitalNCT07711483Written as LISOCABTAGENE MARALEUCEL
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Lisocabtagene Maraleucel
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingPhase 2Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07015242Written as Liso-cel
- Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07194980Written as Lisocabtagene Maraleucel
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeRecruitingPhase 2Aseel AlsouqiNCT05873712Written as Lisocabtagene Maraleucel
- Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1University of NebraskaNCT05621096Written as Liso-cel
- Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationActive, not recruitingPhase 2City of Hope Medical CenterNCT05672173Written as Lisocabtagene Maraleucel
- ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaSuspendedPhase 1/2Fred Hutchinson Cancer CenterNCT07098364Written as Lisocabtagene Maraleucel
- Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 1NeoImmuneTechNCT05075603Written as Lisocabtagene Maraleucel
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Active, not recruitingPhase 1/2Juno Therapeutics, a Subsidiary of CelgeneNCT03331198Written as JCAR017 (lisocabtagene maraleucel)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaWithdrawnPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06313996Written as Liso-cel
- Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasActive, not recruitingPhase 2Patrick C. Johnson, MDNCT05583149Written as LISOCABTAGENE MARALEUCEL
- MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03642626Written as Breyanzi Injectable Product
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingPhase 2CelgeneNCT04245839Written as JCAR017
- A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedPhase 2Juno Therapeutics, a Subsidiary of CelgeneNCT03744676Written as lisocabtagene maraleucel
- Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin LymphomaCompletedPhase 2CelgeneNCT03484702Written as JCAR017
- A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)TerminatedPhase 1/2CelgeneNCT03743246Written as JCAR017
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedPhase 1Juno Therapeutics, a Subsidiary of CelgeneNCT02631044Written as JCAR017 (lisocabtagene maraleucel) single-dose schedule
- A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWithdrawnPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06205290Written as Liso-cel
- Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)CompletedPhase 2Juno Therapeutics, a Subsidiary of CelgeneNCT03483103Written as lisocabtagene maraleucel
Given in every arm · 4 — lisocabtagene maraleucel is usual care beside what is tested
- Emapalumab Prevention of CAR-T Cell Associated ToxicitiesRecruitingPhase 2Marcela V. Maus, M.D.,Ph.D.NCT06550141Written as Lisocabtagene maraleucel
- NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell LymphomaCompletedPhase 1Fred Hutchinson Cancer CenterNCT05359211Written as Lisocabtagene Maraleucel
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT04855253Written as Lisocabtagene Maraleucel Intravenous Suspension
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/2CelgeneNCT03310619Written as JCAR017
As the comparator · 1 — what is tested is compared with lisocabtagene maraleucel
Codes
What other systems call lisocabtagene maraleucel · ClinicalTrials.gg INT015482
- UNII (FDA) 7K2YOJ14X0LISOCABTAGENE MARALEUCELOne source FDA
- RxNorm 2479136One source FDA
- NCI Thesaurus C125192Lisocabtagene MaraleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7K2YOJ14X0 | LISOCABTAGENE MARALEUCEL | One source FDA |
| RxNorm | 2479136 | — | One source FDA |
| NCI Thesaurus | C125192 | Lisocabtagene Maraleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.